% | $
Quotes you view appear here for quick access.

StemCells Inc. Message Board

  • taurusthebullrunner taurusthebullrunner Apr 2, 2012 10:56 AM Flag

    LifeTech Capital issues STEM Report Update April 2, 2012

    uCNS-SC® Phase I PMD Data in Children Shows Unprecedented Results
    Myelination Continued Increasing 3-Months Post-Immunosuppression
    Gains in Motor and/or Cognitive Function in 3 out of 4 Children

    Download Full 8-Page Note with Important Disclosures: Morning Note 04-02-12 STEM
    NOTE: StemCells Inc. will host a live conference call and webcast today, April 2, at 11:00 AM Eastern Time (8:00 AM Pacific Time) to discuss the summary trial results.

    StemCells Inc. announced successful preliminary Phase I data in Pelizaeus-Merzbacher Disease (PMD), a rare hypo-myelination disorder in children. A summary of the trial results were presented March 31st at the 2012 European Leukodystrophy Association (ELA) Families/Scientists Meeting in Paris. StemCells Inc. now intends to proceed to Phase II clinical trials.
    Highlights of the results are:

    • Progressive and durable donor-cell derived myelination in all 4 patients

    • Small but measureable gains in motor and/or cognitive function in 3 of the 4 patients (the 4th patient remained clinically stable)

    • After 1 year, MRI showed changes compatible with increased myelination in the region of the transplantation. The MRI signs of myelination persisted even after immunosuppression was stopped at 9 months and in fact, were also found to progress over time.

    • The development of new myelin signals is unprecedented in patients with connatal PMD and is consistent with HuCNS-SC engraftment.
    These results may also be applicable to other leukodystrophies, as well as more common myelin disorders including transverse myelitis, multiple sclerosis and periventricular white matter injury seen in Cerebral Palsy.

    full report

0.2931-0.0020(-0.68%)1:59 PMEDT